Anthera Pharmaceuticals Provides Business Update and Reports 2015 Fourth Quarter and Fiscal Year Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Piper Jaffray Cuts Price Target on Anthera Pharma (ANTH) to $10 Following 4Q
March 11, 2016 8:31 AM ESTPiper Jaffray maintained an Overweight rating on Anthera Pharma (NASDAQ: ANTH), and cut the price target to $10.00 (from $14.00), following the company's 4Q. Anthera stopped enrollment of the Phase II BRIGHT-SC trial of blisibimod at 57 IgA Nephropathy patients, of which 45 remained on study. Also, Anthera... More
Anthera Pharma (ANTH) Tops Q4 EPS by 10c
March 10, 2016 8:38 AM ESTAnthera Pharma (NASDAQ: ANTH) reported Q4 EPS of ($0.18), $0.10 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $1.92 million versus the consensus estimate of $150 thousand.
Cash and cash equivalents totaled $47 million as of December 31, 2015, compared to $2.6 million as of December 31,... More
